PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study

Abstract Programmed cell death receptor ligand-1 (PD-L1) expression, KRAS (KRASm) and EGFR (EGFRm) mutations may influence non-small cell lung cancer (NSCLC) prognosis. We aimed to evaluate PD-L1 expression, KRASm, and EGFRm and survival among stage III unresected NSCLC patients. Using Danish regist...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Deirdre Cronin-Fenton, Tapashi Dalvi, Naimisha Movva, Lars Pedersen, Hanh Hansen, Jon Fryzek, Elizabeth Hedgeman, Anders Mellemgaard, Torben R. Rasmussen, Norah Shire, Stephen Hamilton-Dutoit, Mette Nørgaard
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/b4c1a9ab9ce54222a8cc1b0d41e549b9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b4c1a9ab9ce54222a8cc1b0d41e549b9
record_format	dspace
spelling	oai:doaj.org-article:b4c1a9ab9ce54222a8cc1b0d41e549b92021-12-02T17:08:23ZPD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study10.1038/s41598-021-96486-22045-2322https://doaj.org/article/b4c1a9ab9ce54222a8cc1b0d41e549b92021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-96486-2https://doaj.org/toc/2045-2322Abstract Programmed cell death receptor ligand-1 (PD-L1) expression, KRAS (KRASm) and EGFR (EGFRm) mutations may influence non-small cell lung cancer (NSCLC) prognosis. We aimed to evaluate PD-L1 expression, KRASm, and EGFRm and survival among stage III unresected NSCLC patients. Using Danish registries, we collected data on stage III unresected NSCLC patients diagnosed 2001–2012 and paraffin-embedded tumor tissue from pathology archives. We assessed PD-L1 expression in tumors and tumor-infiltrating immune cells (ICs) by immunohistochemistry ( $$\ge$$ ≥ 1% threshold for PD-L1+). We genotyped KRAS and EGFR. Follow-up extended from 120 days post-diagnosis to death, emigration, or 31/12/2014. We computed median survival using Kaplan–Meier methods, and hazard ratios (HRs) using Cox regression associating the biomarkers with death, adjusting for confounders. Among 305 patients, 48% had adenocarcinoma; 38% squamous cell carcinoma. Forty-nine percent had PD-L1+ tumors—51% stage IIIA and 26% KRASm. Few (2%) patients had EGFRm. Median survival in months was 14.7 (95% CI = 11.8–17.9) and 13.4 (95% CI = 9.5–16.3) in PD-L1+ and PD-L1− tumors, respectively. KRASm was not associated with death (HR = 1.06, 95% CI = 0.74–1.51 versus wildtype). PD-L1+ tumors yielded a HR = 0.83 (95% CI = 0.63–1.10); PD-L1+ ICs a HR = 0.51 (95% CI = 0.39–0.68). Tumor expression of PD-L1 did not influence survival. PD-L1+ ICs may confer survival benefit in stage III unresected NSCLC patients.Deirdre Cronin-FentonTapashi DalviNaimisha MovvaLars PedersenHanh HansenJon FryzekElizabeth HedgemanAnders MellemgaardTorben R. RasmussenNorah ShireStephen Hamilton-DutoitMette NørgaardNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Deirdre Cronin-Fenton Tapashi Dalvi Naimisha Movva Lars Pedersen Hanh Hansen Jon Fryzek Elizabeth Hedgeman Anders Mellemgaard Torben R. Rasmussen Norah Shire Stephen Hamilton-Dutoit Mette Nørgaard PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study
description	Abstract Programmed cell death receptor ligand-1 (PD-L1) expression, KRAS (KRASm) and EGFR (EGFRm) mutations may influence non-small cell lung cancer (NSCLC) prognosis. We aimed to evaluate PD-L1 expression, KRASm, and EGFRm and survival among stage III unresected NSCLC patients. Using Danish registries, we collected data on stage III unresected NSCLC patients diagnosed 2001–2012 and paraffin-embedded tumor tissue from pathology archives. We assessed PD-L1 expression in tumors and tumor-infiltrating immune cells (ICs) by immunohistochemistry ( $$\ge$$ ≥ 1% threshold for PD-L1+). We genotyped KRAS and EGFR. Follow-up extended from 120 days post-diagnosis to death, emigration, or 31/12/2014. We computed median survival using Kaplan–Meier methods, and hazard ratios (HRs) using Cox regression associating the biomarkers with death, adjusting for confounders. Among 305 patients, 48% had adenocarcinoma; 38% squamous cell carcinoma. Forty-nine percent had PD-L1+ tumors—51% stage IIIA and 26% KRASm. Few (2%) patients had EGFRm. Median survival in months was 14.7 (95% CI = 11.8–17.9) and 13.4 (95% CI = 9.5–16.3) in PD-L1+ and PD-L1− tumors, respectively. KRASm was not associated with death (HR = 1.06, 95% CI = 0.74–1.51 versus wildtype). PD-L1+ tumors yielded a HR = 0.83 (95% CI = 0.63–1.10); PD-L1+ ICs a HR = 0.51 (95% CI = 0.39–0.68). Tumor expression of PD-L1 did not influence survival. PD-L1+ ICs may confer survival benefit in stage III unresected NSCLC patients.
format	article
author	Deirdre Cronin-Fenton Tapashi Dalvi Naimisha Movva Lars Pedersen Hanh Hansen Jon Fryzek Elizabeth Hedgeman Anders Mellemgaard Torben R. Rasmussen Norah Shire Stephen Hamilton-Dutoit Mette Nørgaard
author_facet	Deirdre Cronin-Fenton Tapashi Dalvi Naimisha Movva Lars Pedersen Hanh Hansen Jon Fryzek Elizabeth Hedgeman Anders Mellemgaard Torben R. Rasmussen Norah Shire Stephen Hamilton-Dutoit Mette Nørgaard
author_sort	Deirdre Cronin-Fenton
title	PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study
title_short	PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study
title_full	PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study
title_fullStr	PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study
title_full_unstemmed	PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study
title_sort	pd-l1 expression, egfr and kras mutations and survival among stage iii unresected non-small cell lung cancer patients: a danish cohort study
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/b4c1a9ab9ce54222a8cc1b0d41e549b9
work_keys_str_mv	AT deirdrecroninfenton pdl1expressionegfrandkrasmutationsandsurvivalamongstageiiiunresectednonsmallcelllungcancerpatientsadanishcohortstudy AT tapashidalvi pdl1expressionegfrandkrasmutationsandsurvivalamongstageiiiunresectednonsmallcelllungcancerpatientsadanishcohortstudy AT naimishamovva pdl1expressionegfrandkrasmutationsandsurvivalamongstageiiiunresectednonsmallcelllungcancerpatientsadanishcohortstudy AT larspedersen pdl1expressionegfrandkrasmutationsandsurvivalamongstageiiiunresectednonsmallcelllungcancerpatientsadanishcohortstudy AT hanhhansen pdl1expressionegfrandkrasmutationsandsurvivalamongstageiiiunresectednonsmallcelllungcancerpatientsadanishcohortstudy AT jonfryzek pdl1expressionegfrandkrasmutationsandsurvivalamongstageiiiunresectednonsmallcelllungcancerpatientsadanishcohortstudy AT elizabethhedgeman pdl1expressionegfrandkrasmutationsandsurvivalamongstageiiiunresectednonsmallcelllungcancerpatientsadanishcohortstudy AT andersmellemgaard pdl1expressionegfrandkrasmutationsandsurvivalamongstageiiiunresectednonsmallcelllungcancerpatientsadanishcohortstudy AT torbenrrasmussen pdl1expressionegfrandkrasmutationsandsurvivalamongstageiiiunresectednonsmallcelllungcancerpatientsadanishcohortstudy AT norahshire pdl1expressionegfrandkrasmutationsandsurvivalamongstageiiiunresectednonsmallcelllungcancerpatientsadanishcohortstudy AT stephenhamiltondutoit pdl1expressionegfrandkrasmutationsandsurvivalamongstageiiiunresectednonsmallcelllungcancerpatientsadanishcohortstudy AT mettenørgaard pdl1expressionegfrandkrasmutationsandsurvivalamongstageiiiunresectednonsmallcelllungcancerpatientsadanishcohortstudy
_version_	1718381577504817152

PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study

Ejemplares similares